Among people with sarcoidosis who failed to respond to earlier lines of treatment, the use of abatacept or tofacitinib — medications approved for other inflammatory conditions — appeared safe and effective, according to a Danish report. While neither abatacept (sold as Orencia in the U.S. and Europe) nor…
A study shows therapeutic doses of Atyr Pharma’s experimental therapy efzofitimod were associated with a lower rate of relapse in people with pulmonary sarcoidosis who were tapering oral corticosteroids, a mainstay treatment linked with toxic side effects when given for long periods and at high doses. While the…
A 26-year-old man in Nepal developed pulmonary sarcoidosis after a mild COVID-19 infection, per a new case report that suggests “sarcoidosis as a potential complication of COVID-19,” according to researchers. The man was initially diagnosed with post-COVID fibrosis, or thickening and scarring of lung tissue following a COVID-19 infection.
The activation of signaling pathways associated with immune B-cells may be a key feature that distinguishes sarcoidosis from tuberculosis, according to new research. Both conditions are characterized by the presence of granulomas, or small clumps of inflammatory cells, and can have similar clinical manifestations, such as uveitis, a type…
An immune cell called a type 1 innate lymphoid cell is found at much higher levels in skin granulomas, that is, clumps of immune cells, of people with sarcoidosis relative to those with non-sarcoid skin granulomas, according to research that shows high levels of the cells were also found…
Involvement of the pericardium, a sac-like membrane that surrounds and protects the heart, is an uncommon manifestation of cardiac sarcoidosis that doctors should consider when there’s evidence of heart inflammation, a case report suggests about a woman who reported chest pain during a visit to a clinic. “This case…
The Foundation for Sarcoidosis Research (FSR), a nonprofit dedicated to finding new treatments and improving care for people with sarcoidosis, has nominated 14 new members to its scientific advisory board (SAB), with an aim of further enhancing research and patient care. The FSR SAB includes world-renowned researchers…
A woman in her 50s in Florida who presented with recurrent ministrokes was eventually diagnosed with sarcoidosis only affecting the heart, called isolated cardiac sarcoidosis, a case study reports. “This case highlights the need to consider [cardiac sarcoidosis] as a potential cause of [stroke-like] events in patients with few…
Nonsteroidal immunosuppressants may be a treatment option for people with cardiac sarcoidosis who don’t respond well to corticosteroids or have side effects from using them, a Japanese study suggests. While nonsteroidal immunosuppressants reduced the need for corticosteroids and how active sarcoidosis lesions were for some patients, more research is…
Two early-career scientists each were awarded $150,000 Sarcoidosis Research Fellowship grants from the Foundation for Sarcoidosis Research (FSR) to support projects that aim to investigate the causes of sarcoidosis and improve patient outcomes. The fellowships were awarded to Greer Waldrop, MD, PhD, at the University of California,…
Get regular updates to your inbox.